Research progress of small molecule modulators targeting Toll-like receptor 2
10.16438/j.0513-4870.2023-0552
- VernacularTitle:靶向Toll样受体2的小分子调节剂研究进展
- Author:
Jia-hua KE
;
Dan-lei CHEN
;
Kui CHENG
- Publication Type:Research Article
- Keywords:
TLR2 receptor;
agonist;
inhibitor;
anti inflammation;
tumor immunity
- From:
Acta Pharmaceutica Sinica
2023;58(8):2239-2249
- CountryChina
- Language:Chinese
-
Abstract:
Toll like receptors (TLRs) are the earliest discovered natural immune pattern recognition receptors (PRRs). The abnormality of TLR signal transduction pathway is the key factor leading to chronic inflammatory, cancer, nervous system disease and cardiovascular diseases. The development of TLR agonists and inhibitors has attracted much attention. Currently known TLR2 agonists, such as lipopeptides or their derivatives, have certain limitations in drug development due to their difficult synthesis, easy hydrolysis, and triggering inflammatory cytokine storms, while inhibitors have been rarely reported. New small molecule TLR2 agonists or inhibitors with higher stability are more likely to be developed as tumor immunotherapy or anti-inflammatory drugs.
